Artesunate: developmental toxicity and toxicokinetics in monkeys
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The developmental toxicity, toxicokinetics, and hematological effects of the antimalarial drug, artesunate, were previously studied in rats and rabbits and have now been studied in cynomolgus monkeys. METHODS: Groups of up to 15 pregnant females were dosed on Gestation Days (GD) 20–50 or for 3–7‐day intervals. RESULTS: At 30 mg/kg/day, 6 embryos died between GD30 and GD40. Histologic examination of 3 live embryos (GD26–GD36) revealed a marked reduction in embryonic erythroblasts and cardiomyopathy. At 12 mg/kg/day, 6 embryos died between GD30 and GD45. Four surviving fetuses examined on GD100 had no malformations, but long bone lengths were slightly decreased. At the developmental no‐adverse‐effect‐level (4 mg/kg/day), maternal plasma AUC was 3.68 ng.h/mL for artesunate and 6.93 ng.h/ml for its active metabolite, dihydroartemisinin (DHA). No developmental toxicity occurred with administration of 12 mg/kg/day for 3 or 7 days, GD29–31 or GD27–33 (maternal plasma AUC of 9.84 ng.h/mL artesunate and 16.4 ng.h/mL DHA). Exposures at embryotoxic doses were substantially lower than human therapeutic exposures. However, differences in monkey and human Vss for artesunate (0.5 L/kg vs. 0.18 L/kg) confound relying solely on AUC for assessing human risk. Decreases in reticulocyte count occur at therapeutic doses in humans. Changes to reticulocyte counts at embryotoxic doses in monkeys (≥12 mg/kg/day) were variable and generally minor. CONCLUSIONS: Artesunate was embryolethal at ≥12 mg/kg/day when dosed for at least 12 days at the beginning of organogenesis, but not when dosed for 3 or 7 days, indicating that developmental toxicity of artesunate is dependent upon duration of dosing in cynomologus monkeys. Birth Defects Res (Part B) 83:418–434, 2008. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The economic and social burden of malaria
Sachs, J., & Malaney, P. (2002) · Nature · doi:10.1038/415680a · Cited by 2,248
The burden of malaria in pregnancy in malaria-endemic areas
Steketee, R., Nahlen, B., Parise, M., & Menendez, C. (2001) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.64.28 · Cited by 1,063
Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy
Meshnick, S. R., Taylor, T. E., & Kamchonwongpaisan, S. (1996) · Microbiological Reviews · doi:10.1128/mmbr.60.2.301-315.1996 · Cited by 710
McGready, R., Cho, T., Keo, N. K., Thwai, K. L., Villegas, L., Looareesuwan, S., White, N. J., & Nosten, F. (2001) · Clinical Infectious Diseases · doi:10.1086/324349 · Cited by 178
McGready, R., Cho, T., Samuel, Villegas, L., Brockman, A., van Vugt, M., Looareesuwan, S., White, N. J., & Nosten, F. (2001) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(01)90106-3 · Cited by 114
McGready, R., Brockman, A., Cho, T., Cho, D., van Vugt, M., Luxemburger, C., Chongsuphajaisiddhi, T., White, N. J., & Nosten, F. (2000) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(00)90235-9 · Cited by 110
The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy
Deen, J. L., von Seidlein, L., Pinder, M., Walraven, G. E. L., & Greenwood, B. M. (2001) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(01)90204-4 · Cited by 102
McGready, R., Stepniewska, K., Ward, S. A., Cho, T., Gilveray, G., Looareesuwan, S., White, N. J., & Nosten, F. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0118-y · Cited by 101
Cited by
Discovery, mechanisms of action and combination therapy of artemisinin
Cui, L., & Su, X.-Z. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.68 · Cited by 371
McGready, R., Lee, S., Wiladphaingern, J., Ashley, E., Rijken, M., Boel, M., Simpson, J., Paw, M., Pimanpanarak, M., Mu, O., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70339-5 · Cited by 228
McGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050253 · Cited by 136
“Artemether, like all artemisinin derivatives, can induce foetal resorption if given in high doses to experimental animals during a narrow time window in early gestation [14,15], although recent studies in primates showed no teratogenic effects at dosages equivalent to those currently recommended for antimalarial treat…”
BackgroundDellicour, S., Sevene, E., McGready, R., Tinto, H., Mosha, D., Manyando, C., Rulisa, S., Desai, M., Ouma, P., Oneko, M., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002290 · Cited by 90
“In monkeys, embryolethality was observed following prolonged treatment (12 to 20 d), but there were no malformations [2,4].”
InfluentialMoore, K. A., Simpson, J. A., Paw, M. K., Pimanpanarak, M., Wiladphaingern, J., Rijken, M. J., Jittamala, P., White, N. J., Fowkes, F. J. I., Nosten, F., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00547-2 · Cited by 84
Manyando, C., Mkandawire, R., Puma, L., Sinkala, M., Mpabalwani, E., Njunju, E., Gomes, M., Ribeiro, I., Walter, V., Virtanen, M., et al. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-249 · Cited by 67
Metadata
- Authors
- Clark, R. L., Arima, A., Makori, N., Nakata, Y., Bernard, F., Gristwood, W., Harrell, A., White, T. E. K., & Wier, P. J.
- Venue
- Birth Defects Research Part B: Developmental and Reproductive Toxicology
- Publisher
- Wiley
- Published
- 2008-08
- Volume
- 83
- Issue
- 4
- Pages
- 418-434
- ISSN
- 1542-9733 (ISSN-L)
- 1542-9741
- OpenAlex
- W2023941860
- Cited by
- 68
- References
- 8
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.